EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates on Recent Advancements in Hepatitis D Virus Treatment

Ali Emre Bardak, Nazli Begum Ozturk iD, Merve Gurakar iD, Lynette Sequeira iD, Eda Yildiz iD, Enis Hikmet Ozmert iD, Ramazan Idilman iD, Ahmet Gurakar iD

Viruses · 10.08.2025 · 17 (8) · 1100

DOI: 10.3390/v17081100 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 10.08.2025. Verfasst von Ali Emre Bardak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Boston Medical Center-Brighton, Boston, MA 02135, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis Delta Virus, Hepatitis D, Hepatitis D, Chronic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis D virus (HDV) infection remains a major cause of severe liver disease among hepatitis B virus (HBV)-infected patients, contributing to accelerated progression to cirrhosis and hepatocellular carcinoma. Pegylated interferon-α remains the first-line therapy for chronic HDV infection in most cases. However, despite its approval for HBV and hepatitis C virus (HCV) infections, its use in HDV is largely driven by a lack of other options and is constrained by its limited efficacy, suboptimal durability of response, and a substantial side effect profile. Meanwhile, bulevirtide, an entry inhibitor, became the first agent to be approved for use in chronic HDV infections by the European Medicines Agency (EMA), and several other therapies are currently being investigated as well. In this review, we provide updates on recent advancements in HDV treatment and novel therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis Delta VirusHepatitis DHepatitis D, ChronicHumans

Stichwörter der Autor:innen

HDVantisense oligonucleotidebulevirtidehepatitis D virusinterferon lambdalonafarnibnucleic acid polymersmall interfering RNA

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Medicine, Boston Medical Center-Brighton, Boston, MA 02135, USA.
  • Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.
  • Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Gastroenterology, Ankara University School of Medicine, Ankara 06230, Turkey.

ORCID-Profile: Nazli Begum Ozturk, Merve Gurakar, Lynette Sequeira, Eda Yildiz, Enis Hikmet Ozmert, Ramazan Idilman, Ahmet Gurakar

Zitieren

APA

Bardak, A. E., Ozturk, N. B., Gurakar, M., Sequeira, L., Yildiz, E., Ozmert, E. H., Idilman, R., & Gurakar, A. (2025). Updates on Recent Advancements in Hepatitis D Virus Treatment. Viruses, 17(8), 1100. https://doi.org/10.3390/v17081100

Vancouver

Bardak AE, Ozturk NB, Gurakar M, Sequeira L, Yildiz E, Ozmert EH, et al. Updates on Recent Advancements in Hepatitis D Virus Treatment. Viruses. 2025;17(8):1100. doi:10.3390/v17081100

BibTeX
@article{Bardak2025,
  author = {Bardak, Ali Emre and Ozturk, Nazli Begum and Gurakar, Merve and Sequeira, Lynette and Yildiz, Eda and Ozmert, Enis Hikmet and Idilman, Ramazan and Gurakar, Ahmet},
  title = {Updates on Recent Advancements in Hepatitis D Virus Treatment},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {8},
  pages = {1100},
  doi = {10.3390/v17081100}
}
Kostenlos starten →